Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Florent Grange, Marie Beylot-Barry, Phillipe Courville et al. · Archives of Dermatology · 2007
OBJECTIVES: To describe clinicopathologic features and to identify prognostic factors in a large series of primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. DESIGN: Retrospective multicenter study from the French Study Group on Cutaneous Lymphomas. SETTING: Nineteen departments of dermatology in 10 regions of France. PATIENTS: Sixty patients with a PCLBCL LT included in the registry of the French Study Group on Cutaneous Lymphomas. MAIN OUTCOME MEASURES: Age, sex, outcome, therapy, B symptoms, cutaneous extent, number of lesions, location (leg vs nonleg), serum lactate dehydrogenase level, and MUM-1 and Bcl-2 expression were recorded. Disease-specific survival was used as the main end point. Prognostic factors were identified using a Cox proportional hazards model. RESULTS: Primary cutaneous diffuse large B-cell lymphoma, leg type is characterized by a predilection for the leg (72%), a high proportion of Bcl-2 expression (85%), an advanced age at onset (mean age, 76 years), and frequent relapses and extracutaneous dissemination. The overall 5-year disease-specific survival rate was 41%. Location on the leg and multiple skin lesions were predictive of death in multivariate analysis. Although no variable related to therapy was significantly associated with survival, patients recently treated with combinations of anthracycline-containing chemotherapies and rituximab had a more favorable short-term outcome. CONCLUSIONS: Primary cutaneous diffuse large B-cell lymphoma, leg type is a distinct entity with a poor prognosis, particularly in patients with multiple tumors on the legs. Despite the advanced age of many patients, the prognosis could be improved with combinations of anthracycline-containing chemotherapies and rituximab.
Cited by 261 works. doi:10.1001/archderm.143.9.1144
Authors
- Florent Grange
- Marie Beylot-Barry
- Phillipe Courville
- E. Maubec
- Martine Bagot
- Béatrice Vergier
- Pierre Souteyrand
- L. Machet
- Sophie Dalac
- É. Estève
- Isabelle Templier
- Marie‐Françoise Avril
- Caroline Robert
- Stéphane Dalle
- Liliane Laroche
- Michèle M Delaunay
- P. Joly
- Janine Wechsler
- Tony Petrella
References
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
- WHO-EORTC classification for cutaneous lymphomas
- EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
- Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen
- Primary cutaneous B-cell lymphoma: A unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases
- Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group
- WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects